Pharmacokinetics of a THIOMAB™ antibody drug conjugate (TDC): DMUC4064A in a phase 1 study with platinum-resistant ovarian cancer

被引：1
|
作者：
Garg, Amit
She, Gaohong
Donatello, Ian
Kagedal, Matts
Leipold, Douglas D.
Saad, Ola
Liu, Joyce
Moore, Kathleen
Hamilton, Erika
Burris, Howard
Wang, Judy
Birrer, Michael
Humke, Eric
Girish, Sandhya
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-CT092
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT092
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer
    Garcia, AA
    O'Meara, A
    Bahador, A
    Facio, G
    Jeffers, S
    Kim, DY
    Roman, L
    GYNECOLOGIC ONCOLOGY, 2004, 93 (02) : 493 - 498
  • [22] A phase II study of ENMD-2076 in platinum-resistant ovarian cancer.
    Matulonis, U.
    Tew, W. P.
    Matei, D.
    Behbakht, K.
    Fleming, G. F.
    Oza, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Phase II study of anlotinib plus pemetrexed for platinum-resistant epithelial ovarian cancer
    Chen, J.
    Wei, W.
    Zheng, L.
    Li, H.
    Feng, Y.
    Wan, T.
    Qiu, J.
    Jiang, X.
    Xiong, Y.
    Li, J.
    Huang, H.
    Song, L.
    Liu, J.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S630 - S631
  • [24] Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: A gynecologic group study
    Fracasso, PM
    Blessing, JA
    Morgan, MA
    Sood, AK
    Hoffman, JS
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) : 2856 - 2859
  • [25] A phase 2 trial of flavopiridol and cisplatin in platinum-resistant ovarian cancer
    Peethambaram, Prema P.
    Burton, Jill K.
    Oberg, Ann L.
    Gomez-Dahl, Leigh C.
    Isham, Crescent R.
    Tibodeau, Jennifer D.
    Chomjak, Tamra L.
    Colevas, A. Dimitrios
    Wright, John J.
    Erlichman, Charles
    Bible, Keith C.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3380S - 3381S
  • [26] A phase II trial of voreloxin in women with platinum-resistant ovarian cancer
    Hirte, H. W.
    McGuire, W.
    Edwards, R.
    Husain, A.
    Hoskins, P.
    Michels, J.
    Matulonis, U.
    Sexton, C.
    Michelson, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective
    Zhao, Yuxi
    Yuan, Hua
    Li, Ning
    Wu, Lingying
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2025, 304
  • [28] Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma
    Sorensen, P
    Hoyer, M
    Jakobsen, A
    Malmström, H
    Havsteen, H
    Bertelsen, K
    GYNECOLOGIC ONCOLOGY, 2001, 81 (01) : 58 - 62
  • [29] A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer
    Manyam, Madhavi
    Stephens, Amanda J.
    Kennard, Jessica A.
    LeBlanc, Jane
    Ahmad, Sarfraz
    Kendrick, James E.
    Holloway, Robert W.
    GYNECOLOGIC ONCOLOGY, 2021, 163 (03) : 481 - 489
  • [30] A Phase 1 and Pharmacodynamic Study of Decitabine in Combination With Carboplatin in Patients With Recurrent, Platinum-Resistant, Epithelial Ovarian Cancer
    Fang, Fang
    Balch, Curt
    Schilder, Jeanne
    Breen, Timothy
    Zhang, Shu
    Shen, Changyu
    Li, Lang
    Kulesavage, Carol
    Snyder, Anthony J.
    Nephew, Kenneth P.
    Matei, Daniela E.
    CANCER, 2010, 116 (17) : 4043 - 4053
12345